Study Number:

Study Gender:

PWG Approval Date:

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane CAS Number: 18107-18-1 Date Report Requested: 10/22/2020 Time Report Requested: 09:05:16 Lab: Battelle

C11049-02

Male

See web page for date of PWG Approval

Test Compound: Trimethylsilyldiazomethane

Male: 1 Day Exposure						
		Treatment Groups (ppm)				
	0	10	25 ppm Hexanes			
Disposition Summary						
Animals Initially In Study	8	8	8			
Scheduled Sacrifice						
Early Deaths						
Survivors Scheduled sacrifice, terminal (SD 1)	0	8	8			
Animals Examined Microscopically	8 8	8	8			
		0	0			
ALIMENTARY SYSTEM						
LIVER	(8)	(8)	(8)			
PHARYNX	(8)	(8)	(8)			
CARDIOVASCULAR SYSTEM						
AORTA	(8)	(8)	(8)			
HEART	(8)	(8)	(8)			
ENDOCRINE SYSTEM						
No Tissues/Organs Examined						
GENERAL BODY SYSTEM						
No Tissues/Organs Examined						
GENITAL SYSTEM						
No Tissues/Organs Examined						
HEMATOLYMPHOID SYSTEM						
No Tissues/Organs Examined						
INTEGUMENTARY SYSTEM						
No Tissues/Organs Examined						
MUSCULOSKELETAL SYSTEM						
No Tissues/Organs Examined						

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 1 Day Exposure						
		Treatment Groups (ppn	n)			
	0	10	25 ppm Hexanes			
NERVOUS SYSTEM						
BRAIN	(8)	(8)	(8)			
NERVE, SCIATIC	(8)	(8)	(8)			
TRIGEMINAL GANGLION	(8)	(8)	(8)			
RESPIRATORY SYSTEM						
LARYNX	(8)	(8)	(8)			
LUNG	(8)	(8)	(8)			
NOSE	(8)	(8)	(8)			
TRACHEA	(8)	(8)	(8)			
SPECIAL SENSES SYSTEM						
No Tissues/Organs Examined						
URINARY SYSTEM						
KIDNEY, LEFT	(8)	(8)	(8)			
No Systemic Lesions						

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

umor Summary Data for Male 1 Day Exposure		Treatment Groups (ppm)			
	0	10	25 ppm Hexanes		
Total Animals with Primary Neoplasms	0	0	0		
Total Primary Neoplasms	0	0	0		
Total Animals with Benign Neoplasms	0	0	0		
Total Benign Neoplasms	0	0	0		
Total Animals with Malignant Neoplasms	0	0	0		
Total Malignant Neoplasms	0	0	0		
Total Animals with Metastatic Neoplasms	0	0	0		
Total Metastatic Neoplasms	0	0	0		
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0		

Test Compound: Trimethylsilyldiazomethane

Male: 1 Day Recovery					
		Treatment Groups (ppm)			
	0	10	25 ppm Hexanes		
Disposition Summary					
Animals Initially In Study	8	8	8		
Scheduled Sacrifice					
Early Deaths		_			
Found Dead		5			
Survivors Scheduled sacrifice, terminal (SD 9)	0	2	0		
Animals Examined Microscopically	8	3 8	8 8		
ALIMENTARY SYSTEM					
LIVER	(8)	(8)	(8)		
PHARYNX	(8)	(8)	(8)		
CARDIOVASCULAR SYSTEM					
AORTA	(8)	(8)	(8)		
HEART	(8)	(8)	(8)		
ENDOCRINE SYSTEM					
No Tissues/Organs Examined					
GENERAL BODY SYSTEM					
No Tissues/Organs Examined					
GENITAL SYSTEM					
No Tissues/Organs Examined					
HEMATOLYMPHOID SYSTEM					
THYMUS	(8)	(7)	(8)		
INTEGUMENTARY SYSTEM					
No Tissues/Organs Examined					
MUSCULOSKELETAL SYSTEM					
No Tissues/Organs Examined					

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

Male: 1 Day Recovery					
		Treatment Groups (ppn	1)		
	0	10	25 ppm Hexanes		
NERVOUS SYSTEM					
BRAIN	(8)	(8)	(8)		
NERVE, SCIATIC	(8)	(8)	(8)		
TRIGEMINAL GANGLION	(8)	(8)	(8)		
RESPIRATORY SYSTEM					
LARYNX	(8)	(8)	(8)		
LUNG	(8)	(8)	(8)		
NOSE	(8)	(8)	(8)		
TRACHEA	(8)	(8)	(8)		
SPECIAL SENSES SYSTEM					
No Tissues/Organs Examined					
URINARY SYSTEM					
KIDNEY, LEFT	(8)	(8)	(8)		
No Systemic Lesions					

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Fumor Summary Data for Male 1 Day Recovery	Treatment Groups (ppm)				
	0	10	25 ppm Hexanes		
Total Animals with Primary Neoplasms	0	0	0		
Total Primary Neoplasms	0	0	0		
Total Animals with Benign Neoplasms	0	0	0		
Total Benign Neoplasms	0	0	0		
Total Animals with Malignant Neoplasms	0	0	0		
Total Malignant Neoplasms	0	0	0		
Total Animals with Metastatic Neoplasms	0	0	0		
Total Metastatic Neoplasms	0	0	0		
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0		

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 5 Day Exposure						
			Treatment G	iroups (ppm)		
	0	0.3	1	3	10	25 ppm Hexanes
Disposition Summary						
Animals Initially In Study	8	8	8	8	8	8
Scheduled Sacrifice						
Early Deaths						
Euthanized, moribund					2	
Found Dead					6	
Survivors						
Scheduled sacrifice, terminal (SD 5)	8	8	8	8		8
Animals Examined Microscopically	8	8	8	8	8	8
ALIMENTARY SYSTEM						
LIVER	(8)	(0)	(0)	(0)	(8)	(8)
PHARYNX	(8)	(0)	(0)	(0)	(8)	(8)
CARDIOVASCULAR SYSTEM						
AORTA	(8)	(0)	(0)	(0)	(8)	(8)
HEART	(8)	(0)	(0)	(0)	(8)	(8)
ENDOCRINE SYSTEM						
No Tissues/Organs Examined						
GENERAL BODY SYSTEM						
No Tissues/Organs Examined						
GENITAL SYSTEM						
No Tissues/Organs Examined						
HEMATOLYMPHOID SYSTEM						
No Tissues/Organs Examined						
INTEGUMENTARY SYSTEM						
No Tissues/Organs Examined						

Test Compound: Trimethylsilyldiazomethane

Male: 5 Day Exposure						
			Treatment G	iroups (ppm)		
	0	0.3	1	3	10	25 ppm Hexanes
MUSCULOSKELETAL SYSTEM No Tissues/Organs Examined						
NERVOUS SYSTEM						
BRAIN	(8)	(0)	(0)	(0)	(8)	(8)
NERVE, SCIATIC	(8)	(0)	(0)	(0)	(8)	(8)
TRIGEMINAL GANGLION	(8)	(0)	(0)	(0)	(8)	(8)
RESPIRATORY SYSTEM						
LARYNX	(8)	(0)	(0)	(8)	(7)	(8)
LUNG	(8)	(8)	(8)	(8)	(8)	(8)
NOSE	(8)	(0)	(0)	(0)	(8)	(8)
TRACHEA	(8)	(0)	(0)	(0)	(8)	(8)
SPECIAL SENSES SYSTEM						
No Tissues/Organs Examined						
URINARY SYSTEM						
KIDNEY, LEFT	(8)	(0)	(0)	(0)	(8)	(8)
No Systemic Lesions						

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Tumor Summary Data for Male 5 Day Exposure	Treatment Groups (ppm)					
	0	0.3	1	3	10	25 ppm Hexanes
Total Animals with Primary Neoplasms	0	0	0	0	0	0
Total Primary Neoplasms	0	0	0	0	0	0
Total Animals with Benign Neoplasms	0	0	0	0	0	0
Total Benign Neoplasms	0	0	0	0	0	0
Total Animals with Malignant Neoplasms	0	0	0	0	0	0
Total Malignant Neoplasms	0	0	0	0	0	0
Total Animals with Metastatic Neoplasms	0	0	0	0	0	0
Total Metastatic Neoplasms	0	0	0	0	0	0
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0	0

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Male: 5 Day Recovery						
			Treatment G	iroups (ppm)		
	0	0.3	1	3	10	25 ppm Hexanes
Disposition Summary						
Animals Initially In Study	8	8	8	8	8	8
Scheduled Sacrifice						
Early Deaths						
Euthanized, moribund					1	
Found Dead					7	
Survivors						
Scheduled sacrifice, terminal (SD 9)	8	8	8	8		8
Animals Examined Microscopically	8	8	8	8	8	8
ALIMENTARY SYSTEM						
LIVER	(8)	(0)	(0)	(0)	(8)	(8)
PHARYNX	(8)	(0)	(0)	(0)	(8)	(8)
CARDIOVASCULAR SYSTEM						
AORTA	(8)	(0)	(0)	(0)	(8)	(8)
HEART	(8)	(0)	(0)	(0)	(8)	(8)
ENDOCRINE SYSTEM						
No Tissues/Organs Examined						
GENERAL BODY SYSTEM						
No Tissues/Organs Examined						
GENITAL SYSTEM						
No Tissues/Organs Examined						
HEMATOLYMPHOID SYSTEM						
No Tissues/Organs Examined						
INTEGUMENTARY SYSTEM						
No Tissues/Organs Examined						

Test Compound: Trimethylsilyldiazomethane

Male: 5 Day Recovery						
			Treatment G	iroups (ppm)		
	0	0.3	1	3	10	25 ppm Hexanes
MUSCULOSKELETAL SYSTEM No Tissues/Organs Examined						
NERVOUS SYSTEM						
BRAIN	(8)	(0)	(0)	(0)	(8)	(8)
NERVE, SCIATIC	(8)	(0)	(0)	(0)	(8)	(8)
TRIGEMINAL GANGLION	(8)	(0)	(0)	(0)	(8)	(8)
RESPIRATORY SYSTEM						
LARYNX	(8)	(0)	(8)	(8)	(8)	(8)
LUNG	(8)	(8)	(8)	(8)	(8)	(8)
NOSE	(8)	(0)	(0)	(0)	(8)	(8)
TRACHEA	(8)	(0)	(0)	(0)	(8)	(8)
SPECIAL SENSES SYSTEM						
No Tissues/Organs Examined						
URINARY SYSTEM						
KIDNEY, LEFT	(8)	(0)	(0)	(0)	(8)	(8)
No Systemic Lesions						

PA02: Neoplastic Lesion Summary with Percent Incidence

Test Compound: Trimethylsilyldiazomethane

CAS Number: 18107-18-1

Tumor Summary Data for Male 5 Day Recovery	Treatment Groups (ppm)					
	0	0.3	1	3	10	25 ppm Hexanes
Total Animals with Primary Neoplasms	0	0	0	0	0	0
Total Primary Neoplasms	0	0	0	0	0	0
Total Animals with Benign Neoplasms	0	0	0	0	0	0
Total Benign Neoplasms	0	0	0	0	0	0
Total Animals with Malignant Neoplasms	0	0	0	0	0	0
Total Malignant Neoplasms	0	0	0	0	0	0
Total Animals with Metastatic Neoplasms	0	0	0	0	0	0
Total Metastatic Neoplasms	0	0	0	0	0	0
Total Animals with Malignant Neoplasms Uncertain Primary Site	0	0	0	0	0	0

Date Report Requested: 10/22/2020 Time Report Requested: 09:05:16 Lab: Battelle

LEGEND

Number of animals examined given for each tissue. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion.

Number of animals with observation reported with percent incidence in parentheses

Phase day range of terminal sacrifice shown in parentheses in disposition summary

SD - Study Day

The 1 Day Exposure animals were exposed for one day and then sacrificed on study day 1 (first day of exposure was study day 0); the 1 Day Recovery animals were exposed for 1 day and then sacrificed on study day 9; the 5 Day Exposure animals were exposed for five days and then sacrificed on study day 5; the 5 Day Recovery animals were exposed for five days and then sacrificed on study day 5.

** END OF REPORT **